Global Plasmid DNA Manufacturing Market, by Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), by Grade (GMP Grade, R&D Grade and Clinical Grade), by Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), by Manufacturing Type (Outsourcing and In-house Manufacturing), by Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 735.67 Million in 2022 and is expected to exhibit a CAGR of 22.5% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The key players in the market are focusing on adoption of inorganic growth strategies such as partnerships, and collaborations, in order to strengthen their market presence in the global plasmid DNA manufacturing market is expected to drive the market growth over the forecast period. For instance, in February 2021, Novartis AG, a global healthcare company, collaborated with Bill & Melinda Gates Foundation, a non-profit foundation fighting disease, inequity, and poverty across the globe. This strategic alliance aims to bring together gene therapy and drug discovery proficiency of Novartis with charitable objectives of Gates Foundation to discover and develop an approachable in vivo gene therapy to treat Sickle cell disease.
Global Plasmid DNA Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.
The COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others are facing problems with regards to the transportation of drugs from one place to another.
The key players operating in the market are focusing on development of DNA vaccines for the treatment of Covid -19. For instance, In April 2020, INOVIO pharmaceuticals Inc. entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of INOVIO's investigational DNA vaccine INO-4800, which currently is in Phase 1 clinical testing in the U.S. for COVID-19 and could potentially advance to Phase 2/3 efficacy trials this summer.
Global Plasmid DNA Manufacturing Market: Key Developments
In June 2021, Charles River Laboratories International, Inc., American pharmaceutical company, announced that it had completed acquisition of Vigene Biosciences, Inc., a premier, gene therapy contract development and manufacturing organization (CDMO), providing viral vector-based gene delivery solutions. Vigene Biosciences offers high-quality, research grade and CGMP plasmid DNA. The acquisition complements Charles River’s existing cell and gene therapy contract manufacturing capabilities and establishes an end-to-end, gene-modified cell therapy solution in the U.S.
In March 2021, Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. expanded their Clinical Manufacturing Supply Agreement in support of Geneos’ ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC).
Browse 58 Market Data Tables and 53 Figures spread through 339 Pages and in-depth TOC on “Global Plasmid DNA Manufacturing Market”- Forecast to 2030, by Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), by Grade (GMP Grade, R&D Grade and Clinical Grade), by Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), by Manufacturing Type (Outsourcing and In-house Manufacturing), by Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
https://www.coherentmarketinsights.com/market-insight/plasmid-dna-manufacturing-market-2593
Key Takeaways of the Global Plasmid DNA Manufacturing Market:
- The global plasmid DNA manufacturing market is expected to exhibit a CAGR of 22.5% during the forecast period. The increasing inorganic strategies such as collaboration by key players in the market to expand product portfolio is expected to drive the segment growth over the forecast period. For instance, , in June 2020, Oxford Biomedica plc, a leading gene and cell therapy group, announced that it had signed a collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the U.K.’s first strategic vaccine development and advanced manufacturing capability. This agreement will involve the organizations working collaboratively to enable the manufacturing of viral vector based vaccines, contributing towards a rapid increase in the U.K. domestic capacity for this specialized field of vaccine manufacturing.
- Among Manufacturing Type, Outsourcing segment is estimated to hold a dominant position in the global plamid DNA manufacturing market over the forecast period. Owing to, the increasing inorganic strategies such as partnership for supply of plasmid DNA by key players in the market. For instance, in June 2021, AGC Biologics, a contract development and manufacturing organization (CDMO), announced that it had partnered with BioNTech, a German-based biotechnology company to further supply plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at AGC’s Heidelberg, Germany facility. Plasmid DNA (pDNA) starting material is an essential component of BioNTech’s mRNA-based vaccine manufacturing process.
- Among regions, North America, is expected to be the most dominant region in the global plasmid DNA manufacturing market, owing to the key players in the market are focused on facility expansions to increase production and research & development activities. For instance, on October 10, 2022, VGXI Inc., a specialized contract developer and manufacturer (CDMO) announced an opening of its new headquarters and manufacturing facility located at Deison Technology Park in Conroe, Texas. U.S.
- Major players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing
